JPH0463860B2 - - Google Patents
Info
- Publication number
- JPH0463860B2 JPH0463860B2 JP10944384A JP10944384A JPH0463860B2 JP H0463860 B2 JPH0463860 B2 JP H0463860B2 JP 10944384 A JP10944384 A JP 10944384A JP 10944384 A JP10944384 A JP 10944384A JP H0463860 B2 JPH0463860 B2 JP H0463860B2
- Authority
- JP
- Japan
- Prior art keywords
- mecobalamin
- present
- ulcers
- peptic
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims description 29
- 229960005321 mecobalamin Drugs 0.000 claims description 28
- 239000011585 methylcobalamin Substances 0.000 claims description 28
- 235000007672 methylcobalamin Nutrition 0.000 claims description 28
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 9
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241000483002 Euproctis similis Species 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010023177 Jejunal ulcer Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical class [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10944384A JPS60255726A (ja) | 1984-05-31 | 1984-05-31 | 消化性潰瘍治療剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10944384A JPS60255726A (ja) | 1984-05-31 | 1984-05-31 | 消化性潰瘍治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60255726A JPS60255726A (ja) | 1985-12-17 |
JPH0463860B2 true JPH0463860B2 (sl) | 1992-10-13 |
Family
ID=14510369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10944384A Granted JPS60255726A (ja) | 1984-05-31 | 1984-05-31 | 消化性潰瘍治療剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60255726A (sl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0835660A1 (en) * | 1996-10-14 | 1998-04-15 | Gaston Edmond Filomena Merckx | Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions |
CA3016391C (en) * | 2016-03-07 | 2024-06-04 | Nippon Zoki Pharmaceutical Co., Ltd. | Sustained drug release sheet for treating nerve injury |
-
1984
- 1984-05-31 JP JP10944384A patent/JPS60255726A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS60255726A (ja) | 1985-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100335023B1 (ko) | 염증성장질환치료용약제학적조성물 | |
EP3091974B1 (en) | Dosage regimen of ferric trimaltol | |
JP3514955B2 (ja) | カルシウム吸収亢進組成物 | |
JP2001106632A (ja) | 緩下剤の効力を高める方法及び組成物 | |
EP0629400A1 (en) | Idebenone compositions for treating Alzheimer's disease | |
US2438106A (en) | Peroral penicillin compositions | |
JPH0463860B2 (sl) | ||
JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
JPH09154535A (ja) | 納豆菌含有組成物 | |
JP5984328B2 (ja) | 独活葛根湯エキス配合剤 | |
JP2584636B2 (ja) | 胃炎治療剤 | |
JPWO2005032569A1 (ja) | 医薬組成物 | |
JPH0131487B2 (sl) | ||
JP2005015414A (ja) | アレルギー性疾患の症状を抑制・緩和するための薬剤または機能性食品 | |
JPS5938204B2 (ja) | 再生不良性貧血治療剤 | |
JPS5938206B2 (ja) | 補酵素qを主成分とする気管支喘息治療剤 | |
NO134185B (sl) | ||
JP2009263384A (ja) | I型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬 | |
JPS5938207B2 (ja) | 腎疾患治療剤 | |
EP2185158B1 (en) | Use of phosphatidylcholine for treating steroid-dependent and steroid-refractory ulcerative colitis | |
JPH0643327B2 (ja) | 免疫賦活剤 | |
JP2000229853A (ja) | 生理痛改善用組成物 | |
JPWO2021062264A5 (sl) | ||
JPH01135718A (ja) | 放射線障害治療剤 | |
KR100631873B1 (ko) | 생체이용율이 증진된 알렌드론산 제제 |